Medicare Advantage Cost Recovery and the 2027 Rate Reset

Humana Inc. is one of the largest U.S. health insurers, with a business concentrated in government-sponsored programs — principally Medicare Advantage, Medicare Supplement, and stand-alone Prescription Drug Plans, alongside a smaller Medicaid and commercial footprint. The company also operates CenterWell, its healthcare services segment spanning primary care centers, home health, hospice, and pharmacy operations.

How it makes money: Humana receives per-member-per-month capitated payments from CMS for MA members and retains the spread between premium revenue and medical costs (the MLR) plus administrative expense. Profitability is therefore a function of (1) CMS rate levels, (2) risk-adjusted coding accuracy, (3) Star Ratings-driven quality bonuses, and (4) medical cost trend. CenterWell generates fee-for-service and value-based revenue, increasingly internal to Humana's own membership.

Customers and scale: The customer is effectively the federal government (via CMS) for the majority of revenue, with members as the end beneficiary. With a $47.8B market cap, 120.08M shares outstanding, and a public float of 119.82M (essentially fully floated), Humana is a large-cap, institutionally held name. Its revenue scale places it among the top handful of U.S. health insurers, though its membership base is far more MA-concentrated than UnitedHealth, Elevance, or CVS/Aetna.

Near-term (next 12 months):

• 2026 pricing actions flow through: Benefit redesign and plan exits taken for the 2026 plan year should drive sequential MLR improvement as the year progresses.
• Utilization normalization: If inpatient and outpatient trend decelerates from the elevated 2024–2025 baseline, margin beats become possible.
• Stars remediation spend: Near-term earnings remain burdened by investment to recover Star Ratings.

Medium-term (2–4 years):

• 2027 MA rate notice: The single most important swing factor; a favorable update resets revenue per member across the book.
• Star Ratings recovery: Returning major contracts to 4-star+ restores quality bonus revenue.
• CenterWell scaling: Growth in value-based primary care and home health, both as internal cost levers and external revenue.
• MLR structural improvement: Network tightening, prior authorization discipline, and care management aimed at bringing the MLR into a sustainable range.

The table above is directional and anchored to the one verified figure — trailing EPS of $10.57 — with prior and projected years shown as approximate ranges to illustrate the trajectory rather than as precise reported results. The narrative is straightforward: revenue has grown modestly while margins compressed sharply, driven by MA utilization above pricing and Star Ratings pressure. The 2026 estimate assumes partial MLR recovery; the 2027 estimate assumes a favorable rate notice plus Stars improvement. The entire investment case rests on whether EPS can climb from $10.57 back toward the low-$20s, which would justify the current $398.36 price on a normalized multiple.

Market size: U.S. national health expenditure exceeds $4.5 trillion annually, with Medicare Advantage alone covering roughly half of all Medicare beneficiaries — a TAM in the hundreds of billions of premium dollars. MA growth has slowed from its historic pace as penetration matures and CMS tightens risk-adjustment and rate policy.

Competitive positioning: Humana is the purest-play large-cap MA insurer, which cuts both ways — maximum leverage to MA margin recovery, maximum exposure to MA-specific regulation. It lacks the diversified commercial and international buffers of larger peers.

Named comparables:

• UnitedHealth Group (UNH): Diversified leader with Optum; the scale and vertical-integration benchmark.
• Elevance Health (ELN): Strong commercial/Medicaid mix with a growing MA book.
• CVS Health (CVS): Aetna MA plus the Caremark pharmacy engine.
• Centene (CNC): Government-program specialist, more Medicaid-weighted.

Humana's differentiation is concentration and CenterWell; its vulnerability is the same concentration.

DCF discussion: A discounted cash flow framework for Humana hinges almost entirely on the normalized MLR and the terminal margin assumption. Assuming a stabilized MLR in the high-80s, mid-single-digit revenue growth, and a ~9–10% cost of equity (supported by the 0.74 beta), a normalized EPS base in the low-$20s discounted back at a market-like multiple produces a fair value range that brackets the current $398.36 price. The DCF is highly sensitive to the terminal margin: a 100bp permanent MLR improvement is worth materially more than a year of rate upside, which is why the Stars and CenterWell levers matter more than any single rate notice.

Comparable multiples:

On trailing EPS of $10.57, HUM's 37.7x P/E looks rich; on normalized EPS it sits at a modest premium to UNH and a discount to nothing in particular — the market is paying for the recovery. The multiple is fair if execution delivers; it is expensive if the 2027 rate notice disappoints.

• Regulatory/rate risk: An unfavorable 2027 MA rate notice would undercut the entire margin recovery thesis and force a re-rating of the normalized EPS estimate.
• Star Ratings execution risk: Failure to recover 4-star+ ratings on major contracts would permanently impair quality bonus revenue and member retention.
• Medical cost trend risk: Resurgent utilization (inpatient, behavioral, specialty pharmacy) could keep the MLR elevated despite pricing actions.
• Concentration risk: Heavy reliance on individual MA and on CMS as effectively a single payer magnifies the impact of any policy change.
• Valuation risk: After a 144% 52-week move, the stock embeds a successful recovery; any disappointment faces a de-rating from a high base, and the low 2.69% short interest means no squeeze cushion.